You might also be interested in:

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion (PHOTO)

Lausanne, Switzerland (ots) - Patients will be recruited in North America, Europe, South America and the Asia ...

Qingdao, the cradle of The Wandering Earth and Crazy Alien

Qingdao, China (ots) - - Picture available via - - Picture ...

InnoGames boosts mobile revenues by 37 percent in 2018 / Online game developer and publisher reports double-digit percentage revenue growth in its 12th year on the market

Hamburg (ots) - InnoGames, Germany's leading developer and publisher of mobile and online games, today published ...

06.11.2006 – 20:37

DocCheck AG

euro adhoc: DocCheck AG
DocCheck® AG's growth rate and sales forecast continue to increase in the 3rd quarter

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@


In the 3rd quarter of 2006 DocCheck AG, Cologne, (ISIN DE0005471007 // Symbol 547100) has achieved sales totalling 3.3 million euro. This corresponds to a growth rate of 33 per cent when compared to the 3rd quarter of 2005 (2.5 million euro).  Earnings before interest and taxes (EBIT) improved during this period and increased from 0.14 million euro to 0.2 million euro.  In the first nine months, sales increased by 19 per cent rising from 8 million euro to 9.4 million euro and earnings before taxes grew by 140 per cent from 0.26 million euro to 0.62 million euro. This means that by the end of the 3rd quarter, the operating result for the whole of the financial year 2005 has already been exceeded (0.5 million euro). Profit per share amounts to 10 cent in the first nine months (7 cent for the same period in the previous year). Both divisions increased their sales. The DocCheck® division had a 12 per cent increase in sales, rising from 4.1 million euro to 4.6 million euro when compared to the same period in the previous year, as it benefited both from organic growth and for the first time, from consolidation of the new DocCheckShop site in Leipzig in the 3rd quarter. The antwerpes + partner division continues to record an increase in new business. Sales increased by 29 per cent when compared to the same period in the previous year, rising from 3.8 million euro to 4.9 million euro. DocCheck AG is increasing its sales forecast for the whole of the financial year 2006 from 12.3 million euro to between 12.8 and 13 million euro. When compared to the previous year's sales totalling 11.2 million euro, this represents an increase in sales of between 14 per cent and 16 per cent.

@@start.t2@@end of announcement                                                 euro adhoc 06.11.2006 20:00:00

ots Originaltext: DocCheck AG
Im Internet recherchierbar:

Further inquiry note:
Tanja Mumme
+49 (0)221 92053 139

Branche: Computing & Information Technology
ISIN:      DE0005471007
WKN:        547100
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bayerische Börse / free trade

Original content of: DocCheck AG, transmitted by news aktuell

All Releases
Subscribe to DocCheck AG
  • Printable version
  • PDF version

Topics in this relase